Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib
Wei Jiang, MD,
Ruting Guan, PhD,
Yang W. Shao, PhD,
Bo Wang, PhD,
Yina Wang, MD
Affiliations
Wei Jiang, MD
Department of Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Ruting Guan, PhD
Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People’s Republic of China
Yang W. Shao, PhD
Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People’s Republic of China
Bo Wang, PhD
Department of Pathology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China
Yina Wang, MD
Department of Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China; Corresponding author. Address for correspondence: Yina Wang, MD, Department of Oncology, College of Medicine, Zhejiang University Department of Oncology, First Affiliated Hospital, Hangzhou, People’s Republic of China.